• Dechra acquires rights for horse drug


Dechra acquires rights for horse drug

Jan 31 2012

Dechra, the UK-based veterinary pharmaceuticals group has secured worldwide rights of a new drug used to treat lameness in horses.

The deal is worth more than £5 million. The agreement with Bexinc covers the rights to the drug, HY-50, everywhere but Canada.

HY-50 is used for intra-articular (IA) or intravenous (IV) treatment of lameness in horses caused by joint dysfunction.

In Europe it is the only single injection to deliver 50mg of sodium hyaluronate and having both IA and IV indications. 

For the 12 months up to February 28th 2011, HY-50 earned revenue of $2.2 million and operating income of $1.0 million. 

Ian Page, Dechra group chief executive, said: "This product acquisition further strengthens our specialist equine portfolio and will be earnings enhancing in the first full year of ownership."

Earlier this month, Dechra announced it is to launch a phenylpropanolamine product to treat canine USMI to the Irish market.

Posted by Neil Clark

Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


Lab Asia 2023

Oct 10 2023 Hybrid event

MicroTAS 2023

Oct 15 2023 Katowice, Poland

ISPPP 2023

Nov 05 2023 Vienna, Austria

SETAC North America

Nov 12 2023 Louisville, KY, USA

Eastern Analytical Symposium

Nov 13 2023 Plainsboro, NJ, USA

View all events